QualityDipStocks / Health Care · Medical instruments
UFP Technologies UFPT
Outside our quality screen, so we don’t track its dips. It’s 15% below its 52-week high.
Outside our quality screen, 6% under its Market Value. No fair value estimate for now: there isn’t enough data.
- Fair value est.
- n/a
- Market Value
- $301.37price −6%
- Off 52-wk high
- −15%
- Risk vs market
- Above marketbeta 1.31
5 bullish · 3 bearish See why
Repriced or dip?
Dip: business intact
The price is 15% below its 52-week high (Aug 4), but the business held up: net cash (cash minus debt) +0.4% of market cap since the high, shares outstanding fewer shares, each owns more, revenue +3.7%.
Some numbers held up (net cash (cash minus debt) +0.4% of market cap since the high, shares outstanding fewer shares, each owns more, revenue +3.7%), others slipped (revenue growth rate −3.9 pts). The price is 15% below its 52-week high.
The price is 15% below its 52-week high, and the business changed too: revenue growth rate −3.9 pts.
Within 10% of its 52-week high, so there is no dip to judge yet.
The evidence 9 numbers, high vs now
- Revenue, last 12 months$609M → $632M (+3.7%)held up
- Revenue growth rate+11.2% → +7.3% a year (−3.9 pts)changed
- Earnings per share, 12 months$8.80 → $9.33 (+6.1%)held up
- Operating margin15.2% → 15.3% (0.0 pts)held up
- Shares outstanding−0.7% (fewer shares, each owns more)held up
- Net cash (cash minus debt)+0.4% of market cap since the highheld up
- Stock vs its sector (Health Care)stock −15%, sector median +4% since Aug 4about the same
- Price fall vs business numbersprice −15%, revenue/EPS/FCF median +5% (shown, not scored)
- Valuation multipleP/E 38.1× at the high → 30.4× now (shown, not scored)
Business numbers as reported at the high (12 months to Mar 31, 2026) vs the latest filing (12 months to Jun 30, 2026). Each measure is scored from −1 (business changed) to +1 (business intact) and weighted: revenue, earnings per share, free cash flow, operating margin, revenue growth rate, share count, net cash and the move vs its sector. 60 or more reads as a dip, 40 or less as a repricing. Analyst estimates are not in our data, so they are not used. How to read it
Data-based read, not advice.
Priced in
How much growth the market assumed at the 52-week high, the low and today (a reverse DCF).
52-wk high: P/E 38.1×; 52-wk low: P/E 21.2×; now: P/E 30.4×.
| High | Low | Now | |
|---|---|---|---|
| Price | $334.84Aug 4 | $185.45Apr 29 | $283.97 |
| Implied growth | n/a | n/a | n/a |
| P/E | 38.1× | 21.2× | 30.4× |
| EV/Sales | 4.5× | 2.6× | 3.7× |
What this means: a lower P/E than at the high means you pay less for each dollar of profit than buyers did then.
How it’s computed
Reverse DCF: the same 10-year free-cash-flow model as our fair value estimate (9.5% discount rate, growth for years 1–5 fading to 3% by year 10, 3% after), solved for the growth that makes it equal the market value at each price. For the high and the low we use only the filings that were public on that day, so nothing from a later report leaks back. Market value = that close × diluted shares. P/E = market value / 12-month net income; Price / FCF = market value / 12-month free cash flow; EV / Sales = (market value + debt − cash) / 12-month revenue. Hidden when the share count moved over 20% (split, merger), free cash flow is negative, or the company reports in another currency.
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for UFPT: Capital spending isn't tagged for the latest period in SEC XBRL data. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much UFPT moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 3.8× the S&P 500’s.
- Beta vs S&P 500
- 1.31
- Volatility
- 49% vs 13% SPY
- Correlation SPY
- 0.34
- Correlation QQQ
- 0.28
How it ranks
Where UFPT stands vs every one of the 1,996 stocks we cover that has the number. Longer bar = better.
Not in the top quarter on any of these 4 measures
- Dividends + buybacks yield0% · cash paid out or used to retire shares, vs market capLowest 1%of 1,836
- Revenue growth, last 12 months+7.3% · vs the 12 months beforeLowest 40%of 1,814
- Operating margin15% · of sales kept as operating profitTop 40%of 1,288
- Return on invested capital14% · profit per dollar of capitalTop 36%of 838
From SEC filings and our fair value estimate model. A ranking, not advice.
Valuation details
MV $301.37 · FCF value $96.81
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
GrowthSales compounded 19% a year from FY2022 to FY2025.
ProfitabilityReturn on equity of 17% over the last 12 months.
GrowthDiluted EPS grew 15% to $8.75 in FY2025.
Balance sheetDebt / equity of 0.3×, below the 0.6× median for the 126 Health Care companies we cover.
ValuationTrades 5.8% below its Market Value of $301.37, the average price paid since the Aug 3 filing.
Top bearish points 3 of 5
GrowthSales growth slowed to 7% over the last 12 months, from 19% a year over the prior three fiscal years.
ProfitabilityGross margin of 28%, below the 62% median for the 146 Health Care companies we cover.
RiskReports earnings Nov 3 (consensus EPS $2.63): results can move the price sharply and reset Market Value.
All fundamentals
P/E 30.4 · ROE 17% · Sales +7%
Valuation
- P/E
- 30.4×Health Care median 29.0×
- Price / FCF
- n/anot reported in its SEC filings
- FCF yield
- n/anot reported in its SEC filings
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 3.48×
- Price / book
- 4.76×
- Market cap
- $2.2Blisted
- Enterprise value
- $2.3B
Growth
- Revenue, 12 months
- $632M
- Sales growth, 12 months
- +7.3%vs the 12 months before
- Sales growth, 3 yrs
- +19.4%/yrfrom FY2022
- Diluted EPS, 12 months
- $9.25
- EPS growth, last FY
- +15.4%
- Net income, 12 months
- $72M
- Net income growth
- +8%12 months vs before
Profitability
- Gross margin
- 28.5%
- Operating margin
- 15.3%
- Net margin
- 11.4%
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- 17%
- Return on invested capital
- 14%
Balance sheet
- Cash & short-term inv.
- $9M
- Total debt
- $117M
- Net cash
- −$108M
- Debt / equity
- 0.25×
- Interest coverage
- 12.4×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- n/anot reported in its SEC filings
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +0.2%diluted shares vs a year ago
- Stock-based comp
- $10M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From UFP Technologies’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $0.0B · Sales +15%
- Free cash flow, 12 months$0.0B
- Free-cash-flow yield1.4%
- Free-cash-flow margin6%
- Gross margin28%
- Operating margin16%
- Return on invested capital14%
- Return on equity17%
- Sales growth (latest quarter vs year-ago quarter)+15%
- Net debt / EBITDA1.1×
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $283.97
- 52-wk lowlowest close, 1 year$185.45−34.7%
- PriceMon Nov 2 close$283.97you are here
- Market Valueavg paid since Aug 3$301.37+6.1%
- 52-wk highhighest close, 1 year$334.84+17.9%
Momentum & 52-week range
RSI 44 · 5 days −2.5%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Next report
Nov 3
- DateTue Nov 3, after the close
- Consensus EPS$2.63
- Year-ago EPS$2.39
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
UFPT is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on UFP Technologies in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 1:01 PM ET.
Compare with peers
Closest in size in Medical instruments
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.